# PepGen Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/PepGen Inc.). ## Overview PepGen Inc. is a U.S.-based clinical-stage biotechnology company developing oligonucleotide therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. The company was founded around technology spun out from the University of Oxford and MRC and is focused on advancing treatments for severe neuromuscular and neurologic diseases, including myotonic dystrophy type 1. ## Products & services • EDO peptide delivery platform • PGN-EDODM1 for myotonic dystrophy type 1 • Oligonucleotide therapeutic candidates • Preclinical and clinical-stage neuromuscular programs - **EDO platform technology** (0%) — Cell-penetrating peptide delivery technology used to improve oligonucleotide uptake and tissue delivery. - **Lead therapeutic candidate** (0%) — PGN-EDODM1, an investigational therapy targeting the underlying cause of DM1. - **Pipeline development programs** (0%) — Additional oligonucleotide candidates for severe neuromuscular and neurologic diseases. - **Research and development services** (0%) — Internal discovery, preclinical testing, and clinical development activities supporting the pipeline. - EDO peptide delivery platform - PGN-EDODM1 for myotonic dystrophy type 1 - Oligonucleotide therapeutic candidates - Preclinical and clinical-stage neuromuscular programs ## Customers PepGen does not currently have commercial customers because its programs are still in development. Its future buyers, if approved, would likely be specialty physicians, hospitals, and treatment centers serving patients with rare neuromuscular and neurologic diseases. The company also expects potential commercialization to involve payers and, in some markets, strategic partners or distributors. - **Rare disease patients** (primary) — Patients with severe neuromuscular and neurologic diseases who would receive the therapy if approved. - **Specialist prescribers** (primary) — Neuromuscular specialists and key opinion leaders who influence treatment adoption in rare disease markets. - **Healthcare providers** (secondary) — Hospitals, clinics, and treatment centers that would administer or dispense the product. - **Payers** (secondary) — Insurers and reimbursement bodies that affect access, pricing, and uptake after approval. - **Commercial partners** (emerging) — Potential distributors, contract sales forces, or strategic collaborators outside the U.S. - Patients with rare neuromuscular diseases, especially DM1 - Specialist physicians who prescribe therapies for rare disease care - Hospitals and treatment centers administering advanced therapies - Payers and reimbursement systems that determine access and coverage - Potential commercial partners in non-U.S. markets ## Geography PepGen is headquartered in Boston, Massachusetts, and is incorporated in Delaware, with origins in the U.K. through PepGen Limited. The company currently has no commercial infrastructure in any geography, but it expects future commercialization to begin in the U.S. and potentially expand to selected other territories through partners or its own sales organization. - Headquartered in Boston, Massachusetts - Incorporated in Delaware after U.K. origins - No current commercial infrastructure in any geography - U.S. expected to be the first commercialization market - Selected ex-U.S. markets may use partners or distributors ## Strategy PepGen's strategy is centered on advancing its EDO platform and lead DM1 program through clinical development toward regulatory approval. The company also aims to expand the platform into additional severe diseases with high unmet need, while deciding whether future commercialization should be direct in the U.S. or partner-led in other territories. - **Clinical development of PGN-EDODM1** (short-term) — The lead program is the main value driver and the basis for any future approval or commercialization. - **Platform validation and pipeline expansion** (medium-term) — A broader pipeline reduces dependence on a single asset and increases the value of the EDO technology. - **Commercialization planning** (medium-term) — Rare-disease launch strategy must match the size and concentration of the prescriber base. - Advance PGN-EDODM1 through clinical development - Validate the EDO platform in skeletal and other target tissues - Expand into additional severe neuromuscular and neurologic diseases - Build a targeted rare-disease commercialization model if approved - Use partners or distributors in selected non-U.S. markets ## Risks PepGen is highly dependent on the success of a single lead candidate and on the outcome of clinical and regulatory development. As a clinical-stage biotech, it also faces financing risk, manufacturing and supplier concentration risk, and the possibility that its platform or product candidates do not show sufficient safety, efficacy, or commercial differentiation. - **Dependence on PGN-EDODM1** [critical] — The company states it is substantially dependent on the success of its lead product candidate. - **Clinical and regulatory failure** [critical] — If trials do not demonstrate adequate safety or efficacy, approval and commercialization may not occur. - **Financing and going-concern risk** [critical] — The company expects to need additional capital and has disclosed substantial doubt about continuing as a going concern. - **Single-source supplier dependence** [high] — Key components, API, and finished product manufacturing rely on limited suppliers. - **China and third-party manufacturing exposure** [medium] — Some vendors operate outside the U.S., including in China, creating BIOSECURE and transition risk. - **Intellectual property protection** [high] — The EDO platform depends on licensed patents, know-how, and enforceable IP rights. - Lead program concentration creates high single-asset dependence - Clinical trials may fail to show safety or efficacy - Regulatory approval is uncertain and can be delayed - Additional capital will be needed to fund development - Single-source and China-linked suppliers create supply risk - IP protection is critical to defend the EDO platform ## Accounting PepGen's financial statements are dominated by R&D expense estimation, stock-based compensation, and fair-value accounting for cash equivalents and marketable securities. Because it has no product revenue, investors should focus on how clinical trial accruals, vendor obligations, and going-concern disclosures affect reported losses and liquidity assumptions. - **Research and development accruals** — Can shift reported operating losses between quarters - **Stock-based compensation** — Affects operating loss and diluted share analysis - **Fair value of cash equivalents and marketable securities** — Influences non-operating results - **Going-concern assessment** — Important for liquidity and financing risk disclosure - R&D accruals depend on trial progress and vendor invoices - Stock-based compensation is a major non-cash expense - Cash and treasury holdings drive interest income - No product revenue means losses are driven by operating spend - Going-concern judgments affect liquidity disclosure --- *Last updated: 2026-04-29T04:48:11.529666+00:00*